$599

Madrigal Whistleblower Lawsuit; Kailera Q3 ’26 Earnings; Roche Ph3 Enicepatide CVOT; Abbott and Novo APAC Partnership; Pfizer Posts Another Ph3 Berobenatide Study; Novo Cagrisema BP Trial; New Lilly Ph1 Asset; AZ to Acquire Rhythm?; Amgen Repatha RWE Data

A series of cardiometabolic-related news items has been observed from Madrigal, Kailera, Roche, Abbott, Pfizer, Novo, Lilly, AstraZeneca, and Amgen. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here